Basit öğe kaydını göster

dc.contributor.authorBernay, I
dc.contributor.authorSahin, M
dc.date.accessioned2020-06-21T11:31:55Z
dc.date.available2020-06-21T11:31:55Z
dc.date.issued1994
dc.identifier.issn0363-9762
dc.identifier.urihttps://doi.org/10.1097/00003072-199404000-00016
dc.identifier.urihttps://hdl.handle.net/20.500.12712/9936
dc.descriptionWOS: A1994NG03700016en_US
dc.descriptionPubMed: 8004871en_US
dc.description.abstractVipoma syndrome, or the diarrheogenic syndrome, is often caused by a pancreatic islet cell tumor or a retroperitoneal neural tumor and is mainly characterized by watery diarrhea, hypokalemia, and achlorhydria. Vasoactive intestinal polypeptide (VIP) Is generally the mediator in most cases. Intestinal uptake of Tc-99m MDP in a 32-year-old man with Vipoma syndrome is reported. He had normal calcium and phosphate levels. Multiple intestinal biopsies revealed no metastatic calcifications, necrosis, or amyloidosis, but only diffuse intestinal edema and an 80-centimeter-long ischemic segment in the ileum. A synthetic somatostatin analog that was administered to the patient can also be the reason for the intestinal concentration of Tc-99m MDP in this case. To our knowledge, intestinal accumulation of a bone agent in the Vipoma syndrome has not been described.en_US
dc.language.isoengen_US
dc.publisherLippincott-Raven Publen_US
dc.relation.isversionof10.1097/00003072-199404000-00016en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleIntestinal Uptake of Tc-99M Mdp in A Patient With Vipoma Syndromeen_US
dc.typearticleen_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume19en_US
dc.identifier.issue4en_US
dc.identifier.startpage348en_US
dc.identifier.endpage349en_US
dc.relation.journalClinical Nuclear Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster